Title |
Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
|
---|---|
Published in |
Frontiers in Pediatrics, August 2015
|
DOI | 10.3389/fped.2015.00070 |
Pubmed ID | |
Authors |
Angelica Maria Garzon, William Beau Mitchell |
Abstract |
Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go on to have chronic ITP. In those children with chronic ITP who need treatment, standard therapies for acute ITP may have adverse effects that complicate their long-term use. Thus, alternative treatment options are needed for children with chronic ITP. Thrombopoietin receptor agonists (TPO-RA) have been shown to be safe and efficacious in adults with ITP, and represent a new treatment option for children with chronic ITP. One TPO-RA, eltrombopag, is now approved for children. Clinical trials in children are ongoing and data are emerging on safety and efficacy. This review will focus on the physiology of TPO-RA, their clinical use in children, as well as the long-term safety issues that need to be considered when using these agents. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 25% |
Switzerland | 1 | 25% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 32 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 16% |
Researcher | 5 | 16% |
Student > Bachelor | 4 | 13% |
Student > Postgraduate | 3 | 9% |
Student > Ph. D. Student | 2 | 6% |
Other | 3 | 9% |
Unknown | 10 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 50% |
Nursing and Health Professions | 2 | 6% |
Business, Management and Accounting | 1 | 3% |
Social Sciences | 1 | 3% |
Agricultural and Biological Sciences | 1 | 3% |
Other | 0 | 0% |
Unknown | 11 | 34% |